Role of PI3K and EGFR in Oral Cancer Progression and Drug Resistance

Manzar Alam¹ and Rajakishore Mishra²

¹Centre for Life Sciences, School of Natural Sciences, Central University of Jharkhand, Ratu-Lohardaga Road, Brambe, Ranchi-835205, Jharkhand, INDIA.
²Centre for Life Sciences, School of Natural Sciences, Central University of Jharkhand, Ratu-Lohardaga Road, Brambe, Ranchi-835205, Jharkhand, INDIA.

Corresponding Authors: manzar987@gmail.com; rajakishore.mishra@cuj.ac.in

ABSTRACT

Oral cancer is one of the most common cancers in the world and India. Signaling molecules play an important role in Oral Squamous Cell Carcinoma (OSCC). PI3K and EGFR signalling molecules are known to be deregulation in most cancers including oral cancer. These are associated with oral cancer progression and drug resistance. PI3K and EGFR signalling molecules have been linked to the examined resistance developed to radiation and chemotherapy. Crucial signaling molecules that function downstream of the survival pathways, particularly at points where several of these pathways crosstalk that development oral cancer and drug resistance. The main focus of this review is to discuss the role and regulation of PI3K and EGFR in oral cancer drug resistance.

Keywords: Oral Squamous Cell Carcinoma, OSCC, Oral cancer, drug resistance, PI3K, EGFR.

I. INTRODUCTION

Oral cancer is a cancerous lesion present in the mouth and is the sixth most common human malignant diseases in the world [1]. ‘Oral cancer’ can be of various cellular origin, but it mainly occurs in the epithelial cells of oral mucosa. It is also known as squamous cell carcinoma (OSCC). OSCC is the most frequently existing cancer that in the oral cavity. Oral cancer comes under the ‘head and neck squamous cell carcinoma (HNSCC) and most commonly occurs in the tongue, floor of the mouth, cheek, gingival, palate and lip. Recent statistics suggests, OSCC is the most common cancer in men whereas fifth common cancer in women, in Indian subcontinent [1]. Moreover highest mortality rates (77%) occurred in the developing countries. The frequency of OSCC is higher in under-developed countries [2, 3]. In India oral cancer comprises 30% of the total malignancies [4]. There are various types of OSCC, comprising more than 90% of all malignant oral cancer [5].

Chemoresistance is a vital problem for OSCC treatment as a results usually death. The development of drug resistance limits the effectiveness of chemical agents in OSCC [6]. Chemotherapy is an important treatment strategy next to radiotherapy and surgery for the OSCC treatment. Since, the efficacy of the treatment is long-established, accumulating data indicates, these cancer cells do not undertake apoptosis easily, many of these cells endure the selection pressure, survive and metastasitise leading tumor recurrence. [7, 8]. Many novel treatment approaches have been suggested for the management of oral cancer. The progression of chemoresistance phenotype limits to the usefulness of chemical agents in the patients having oral cancer [6].

The phosphoinositide 3-kinase (PI3K) pathway is an important signaling transduction cascade controlling the regulation of cell growth, cellular processes, cell proliferation, survival as well as cell migration. PI3Ks are controlled by different stimuli such as growth factors, hormones, inflammatory mediators, neurotransmitters, antigens and immunoglobulins [9, 10]. Epidermal growth factor receptor (EGFR) is a transmembrane cell-surface receptor. It is a tyrosine kinase (TK) receptor [11] that is commonly activated in epithelial tumors. PI3K and EGFR are involved in oral cancer and drug resistance. The aim of this article is to review the current carry of PI3K and EGFR signalling molecules in oral cancer progression and drug resistance.

II. CHEMO/DRUG-RESISTANCE IN ORAL CANCER

Commonly, the treatment methods for OSCC such as surgery, chemotherapy, radiotherapy and immunotherapy last for past 20-30 years. In spite of all these progress, to treat patients, no considerable improvement in the prognosis for OSCC has been documented. So initial detection of OSCC is important aspect to deal with oral cancer [12]. Recently, Cisplatin-based concurrent radio-chemotherapy is still the agreed level of quality for treating of cancers. Currently, many new methodologies have been suggested for the treatment of oral cancer, such as targeted therapy against EGFR and induction chemotherapy [13]. Intrinsic and acquired drug/chemoresistance agents contribute to treatment failure in oral patients. Several factors are involved in chemoresistance. Several mechanisms initiate to chemoresistance in OSCC. As chemotherapeutic agents and the prevention of side effects have shown marked improvements, induction (neoadjuvant) chemotherapy
has become available for HNSCC [14]. However, a huge number of HNSCC patients show poor response to combination chemotherapy; thus, drug resistance remains unresolved for head-and-neck oncologists [15]. Early stage cancers of the oral cavity are treated with surgery, radiotherapy and chemotherapy, while advanced stage cancers are normally treated with multi-modality regime, sequential, including surgical resection of primary tumors followed by radiotherapy with or without chemotherapy [16]. Chemoresistance is a well identified phenomenon in which cancer cells become tolerant/resistance to therapeutic/ pharmaceutical treatment. Efforts to increase the efficiency of radiotherapy, particularly in local advanced cancer, include concomitant chemoradiotherapy (CT-RT) or altered fractionated radiotherapy [17]. Chemotherapy, cisplatin-based chemoradiation residue the standard for locoregionally advanced OSCC/ HNSCC [18]. Although advances in radiotherapy and surgery, that remain the standard treatment choice, the mortality frequency has remained mostly unchanged for decades, with a 5-year survival rate of about 50% [19].

III. PI3K SIGNALING PATHWAY IN ORAL CANCER AND DRUG RESISTANCE

PI3K signaling pathway is a key signaling transduction cascade controlling the regulation of cell growth, cellular processes, cell proliferation, survival as well as cell migration. PI3Ks are controlled by different stimuli such as growth factors, hormones, inflammatory mediators, neurotransmitters, antigens and immunoglobulins [9, 10]. Activation of receptor protein tyrosine kinases by various external stimuli leads to the generation of a second messenger called phosphatidylinositol 3,4,5 triphosphate (PIP3), which is generated from phosphatidylinositol 4,5 bisphosphate (PIP2) by activated PI3K. The PIP3 recruits Akt/PKB to the plasma membrane, where it is activated via phosphorylations [20]. Akt/mammalian target of rapamycin (mTOR)/ glycogen synthase kinase 3 beta are downstream molecules of phosphoinositide 3-kinase (PI3K) signaling pathway and involve in apoptosis, cell cycle and cell proliferation. Akt/PKB, as the downstream effectors of PI3K, is activated by Class 1A and Class 1B PI3K, and Class 1A and Class 1B PI3K are activated by tyrosine kinase and G-protein-coupled receptors, respectively [9]. Akt induces cellular survival and suppresses apoptosis by various of stimuli. The phosphorylated Akt (p-Akt) is an activated type of Akt which plays a major role in various human cancers. Akt is a 52 kDa serine or threonine kinase with three isoforms: Akt-1, Akt-2, and Akt-3 [21]. Each isoform is comprised of three distinct regions: an N-terminal pleckstrin homology (PH) domain involved in lipid binding, a kinase domain and a C-terminal ‘tail’. Many studies have identified that Akt may be a potential oncogene in humans and over-expression of phosphorylated Akt/PKB (p-Akt/PKB) has been identified in various cancer, including OSCC [22, 23]. Akt activation is linked with increased cancer cell invasion in various cancer, including OSCC cells [24]. Hence, p-Akt may be a good predictor of cancer aggressiveness. The important function of Akt is to inhibit cell death at multiple steps in the apoptosis signaling pathways. The PI3K/Akt/mTOR or PI3K/Akt/GSK3β pathway may be induced by various mechanisms, all of which more activation of the pathway in tumor cells. The activation of the PI3K/PKB pathway has an antiapoptotic effect. When activated, Akt either negatively or positively regulates the function of many different proteins in the cells [25]. Akt has been identified to phosphorylate Bad and caspase-9 which will lead to blockage of their involvement in transducing an apoptotic cascade [26, 27]. These have indicated that expression of Akt inhibits Bax conformational alter and mitochondrial translocation initiated by chemothapeutic agents. One study informs that Akt may be phosphorylate Bax at Ser184 residue. It also has been proposed that PI3K/Akt pathway is linked with radioresistance both in vivo and in vitro in various cancers, including HNSCC [28]. In addition, Akt activates NFκB through phosphorylation of IκB, translocates to the nucleus and triggers transcription of Bcl-2 and Bcl-xL [29, 30]. Phosphatidylinositol 3-kinase (PI3K)/Akt cell signaling pathways are involved in cancer progression. Upregulation of the PI3K/Akt pathways in tumor cells provide the survival signals. P53 protein is post-translationally altered by a number of biological pathways including MAPK, PI3K-Akt, GSK3β etc and this leads to the alteration of the function of p53 [31].

IV. EGFR SIGNALLING PATHWAY IN ORAL CANCER AND DRUG RESISTANCE

EGFR is a transmembrane cell-surface receptor. It is a tyrosine kinase (TK) receptor [11] that is commonly activated in epithelial tumors. The corresponding mRNA is encoded from 28 exons spanning approximately 190,000 (nucleotides) on chromosome 7p12. It belongs to the ErbB family of receptor tyrosine kinases that also includes ErbB2 (HER-2 or Neu), ErbB3 (HER-3) and ErbB4 (HER-4) [32]. Overexpression of EGFR protein and mRNA is linked with poor prognosis, more tumor growth, metastasis and resistance to protein and chemotherapy [33]. EGFR plays a major role in various human malignancies. It has been identified, overexpressed in up to 90% of cases in OSCC [34]. EGFR activation is found to be linked with the malignant phenotype, blockage of apoptosis, increased proliferation, metastasis and resistance to radiochemotherapy, including OSCC [35]. The activated EGFR leads to the activation of several intracellular signaling pathways, including ERK and Stat-3 pathways [36]. ERK and Stat-3 are the important signaling molecules that come under EGFR [37]. Aberrant activation of the EGFR signaling axis has

This work is licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
been found to play a major role in HNSCC [38]. All these evidences suggest the possible role of EGFR for OSCC progression and chemoresistance. There are the several signaling molecules that lie downstream of EGFR [37]. EGFR activation has been documented in OSCC [34, 39]. EGFR is linked with inhibition of apoptosis, and resistance to radiation and chemotherapy in wide array of tumors, including OSCC [40, 41]. Similarly, aberrant induction of the EGFR signaling has been observed to fuel the progression of HNSCC [38].

V. SUMMARY AND CONCLUSION

Oral cancer is one of the most common cancers in the world and India. Cancer of oral cavity, mainly OSCC are highly prevalent in India. The scientific community involved in the areas of advanced cancer research is increasingly aware of the necessity to analyze the drug resistant mechanisms in different population and to come up with suitable treatment modalities and combination of drugs to treat the patients effectively. There are many ways these oral tumor cells develop resistance to drugs and evade signalling mechanism. Deregulation and activation of PI3K and EGFR signalling molecules are involved in oral cancer progression and drug resistance. Elevated expression of these signalling molecules are associated with many cancers progression, including OSCC and found resistance to radio-chemotherapy. PI3K and EGFR are major contributor to the observed oral cancer progression and resistance to drug. These signalling molecules protect the oral cancer cells from most chemotherapy drugs, causing drug resistance. Since, this review contributes to the better understanding of oral squamous cell tumors and drug resistance through PI3K and EGFR signalling molecules.

ACKNOWLEDGEMENTS

The authors would like to acknowledge the Department of Biotechnology (DBT), New Delhi, Project No. BT/PR4624/MED/30/701/2012 and the CLS, CUI is supported by DBT BUILDER Programme No. BT/PR9028/INF/22/193/2013.

AUTHORS’ CONTRIBUTIONS

RM and MA reviewed the literature, drafted and finalized the manuscript and equal contributions

COMPETING INTERESTS

All authors declare that there are no competing interests and this work has not been published elsewhere.

REFERENCES

[1] Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015). Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012. International Journal of Cancer, 136(5), E359–E386. https://doi.org/10.1002/ijc.29210
[2] Kashyap, T., Pramanik, K. K., Nath, N., Mishra, P., Singh, A. K., Nagini, S., Rana, A., & Mishra, R. (2018). Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3β signaling networks promotes chemoresistance, invasion/migration and stemness via expression of CD44 variants (v4 and v6) in oral cancer. Oral Oncology, 86, 234–243. https://doi.org/10.1016/j.oraloncology.2018.09.028
[3] Parkin D. M. (2001). Global cancer statistics in the year 2000. The Lancet. Oncology, 2(9), 533–543. https://doi.org/10.1016/S1470-2045(01)00486-7
[4] Pramanik, K. K., Singh, A. K., Alam, M., Kashyap, T., Mishra, P., Panda, A. K., Dey, R. K., Rana, A., Nagini, S., & Mishra, R. (2016). Reversion-inducing cysteine-rich protein with Kazal motifs and its regulation by glycogen synthase kinase 3 signaling in oral cancer. Tumor Biology, 37(11), 15253–15264. https://doi.org/10.1007/s13277-016-5362-x
[5] Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2001). Estimating the world cancer burden: Globocan 2000. International Journal of Cancer, 94(2), 153–156. https://doi.org/10.1002/ijc.1440
[6] Alam, M., Kashyap, T., Mishra, P., Panda, A. K., Nagini, S., & Mishra, R. (2019). Role and regulation of proapoptotic Bax in oral squamous cell carcinoma and drug resistance. Head & Neck, 41(1), 185–197. https://doi.org/10.1002/hed.25471
[7] Sankaranarayanan, R., Ramadas, K., Thomas, G., Muwonge, R., Thara, S., Mathew, B., & Rajan, B. (2005). Effect of screening on oral cancer mortality in Kerala, India: A cluster-randomised controlled trial. The Lancet, 365(9475), 1927–1933. https://doi.org/10.1016/S0140-6736(05)6658-5
[8] Alam, M., Kashyap, T., Pramanik, K. K., Singh, A. K., Nagini, S., & Mishra, R. (2017). The elevated activation of NFκB and AP-1 is correlated with differential regulation of Bcl-2 and associated with oral squamous cell carcinoma progression and resistance. Clinical Oral Investigations, 21(9), 2721–2731. https://doi.org/10.1007/s00784-017-2074-6
[9] Barasch, A., Safford, M., & Eisenberg, E. (1998). Oral cancer and oral effects of anticancer therapy. The Mount Sinai journal of medicine, New York, 65(5–6), 370–377.
[10] Wang, C., Liu, X. Q., Hou, J. S., Wang, J. N., & Huang, H. Z. (2016). Molecular Mechanisms of Chemoresistance in Oral Cancer. The Chinese journal of dental research : the official journal of the Scientific
Section of the Chinese Stomatological Association (CSA), 19(1), 25–33. https://doi.org/10.3290/j.cjdr.a35694

[11] Kelland, L. (2007). The resurgence of platinum-based cancer chemotherapy. *Nature Reviews Cancer*, 7(8), 573–584. https://doi.org/10.1038/nrc2167

[12] Seiwert, T. Y., Salama, J. K., & Vokes, E. E. (2007). The concurrent chemoradiation paradigm—general principles. *Nature clinical practice. Oncology*, 4(2), 86–100. https://doi.org/10.1038/ncponc0714

[13] Wymann, M. P., Zvelebil, M., & Laffargue, M. (2003). Phosphoinositide 3-kinase signalling—which way to target?. *Trends in pharmacological sciences*, 24(7), 366–376. https://doi.org/10.1016/S0165-6147(03)00163-9

[14] Hawkins, P. T., Anderson, K. E., Davidson, K., & Stephens, L. R. (2006). Signalling through Class I PI3Ks in mammalian cells. *Biochemical Society transactions*, 34(Pr 5), 647–662. https://doi.org/10.1042/BST0340647

[15] Callaghan, T., Antczak, M., Flickinger, T., Raines, M., Myers, M., & Kung, H. J. (1993). A complete description of the EGF-receptor exon structure: implication in oncopgenic activation and domain evolution. *Oncogene*, 8(11), 2939–2948.

[16] Moore, S. R., Johnson, N. W., Pierce, A. M., & Wilson, D. F. (2000). The epidemiology of mouth cancer: a review of global incidence. *Oral diseases*, 6(2), 65–74. https://doi.org/10.1111/j.1601-0825.2000.tb00104.x

[17] Georges, P., Rajagopalan, K., Leon, C., Singh, P., Ahmad, N., Nader, K., and Kubicek, G. J. (2014). Chemotherapy advances in locally advanced head and neck cancer. *World Journal of Clinical Oncology*, 5(5), 966. https://doi.org/10.5306/wjco.v5.i5.966

[18] Cognetti, F., Pinarö, P., Ruggeri, E. M., Carlini, P., Perrino, A., Impiombato, F. A., Calabresi, F., Chilelli, M. G., & Giannarelli, D. (1989). Prognostic factors for chemotherapy response and survival using combination chemotherapy as initial treatment of advanced head and neck squamous cell cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 7(7), 829–837. https://doi.org/10.1200/JCO.1989.7.7.829

[19] Bourhis, J., Wilson, G., Wibault, P., Janot, F., Bosq, J., Armand, J. P., Luboinski, B., Malaise, E. P., & Eschwege, F. (1994). Rapid Tumor Cell Proliferation After Induction Chemotherapy in Oropharyngeal Cancer: The Laryngoscope, 104(4), 468–472. https://doi.org/10.1288/00005537-199404000-00012

[20] Belcher, R., Hayes, K., Fedewa, S., & Chen, A. Y. (2014). Current treatment of head and neck squamous cell cancer. *Journal of surgical oncology*, 110(5), 551–574. https://doi.org/10.1002/jso.23724

[21] Mazeron, R., Tao, Y., Lusinchi, A., & Bourhis, J. (2009). Current concepts of management in radiotherapy for head and neck squamous-cell cancer. *Oral Oncology*, 45(4-5), 402–408. https://doi.org/10.1016/j.oraloncology.2009.01.010

[22] Specenier, P. M., & Vermorken, J. B. (2009). Current concepts for the management of head and neck cancer: chemotherapy. *Oral oncology*, 45(4-5), 409–415. https://doi.org/10.1016/j.oraloncology.2008.05.014

[23] Marsh, D., Suchák, K., Moutsam, K. A., Vallath, S., Hopper, C., Jerjes, W., Upile, T., Kalavrezos, N., Violette, S. M., Weinreb, P. H., Chester, K. A., Chana, J. S., Marshall, J. F., Hart, I. R., Hackshaw, A. K., Piper, K., & Thomas, G. J. (2011). Stromal features are predictive of disease mortality in oral cancer patients. *The Journal of pathology*, 223(4), 470–481. https://doi.org/10.1002/path.2830

[24] Marone, R., Cmiljanovic, V., Giese, B., & Wymann, M. P. (2008). Targeting phosphoinosito3 kinase: moving towards therapy. *Biochimica et biophysica acta, 1784*(1), 159–185. https://doi.org/10.1016/j.bbapap.2007.10.003

[25] Scheid, M. P., & Woodgett, J. R. (2003). Unravelling the activation mechanisms of protein kinase B/Akt. *FEBS letters*, 546(1), 108–112. https://doi.org/10.1016/s0014-5793(03)00562-3

[26] Li, N., Sui, J., Liu, H., Zhong, M., Zhang, M., Yang, W., & Hao, F. (2015). Expression of phosphorylated Akt/mTOR and clinical significance in human ameloblastoma. *International journal of clinical and experimental medicine, 8*(4), 5236–5244.

[27] Yu, Z., Weinberger, P. M., Sasaki, C., Egleston, B. L., Speir, W. F., Haffty, B., Kowalski, D., Camp, R., Rimm, D., Vairaktaris, E., Burtness, B., & Pyrri, A. (2007). Phosphorylation of Akt (Ser473) Predicts Poor Clinical Outcome in Oropharyngeal Squamous Cell Cancer. *Cancer Epidemiology Biomarkers & Prevention*, 16(3), 553–558. https://doi.org/10.1158/1055-9965.EPI-06-0121

[28] Iamaroon, A., & Krisanaprakornkit, S. (2009). Overexpression and activation of Akt2 protein in oral squamous cell carcinoma. *Ooral Oncology*, 45(10), e175–e179. https://doi.org/10.1016/j.oraloncology.2009.06.003

[29] Song, G., Ouyang, G., & Bao, S. (2005). The activation of Akt/PKB signaling pathway and cell survival. *Journal of cellular and molecular medicine, 9*(1), 59–71. https://doi.org/10.1111/j.1582-4934.2005.tb00337.x

[30] Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., & Reed, J. C. (1998). Regulation of cell death protease caspase-9 by phosphorylation. *Science (New York, N.Y.)*, 282(5392), 1318–1321. https://doi.org/10.1126/science.282.5392.1318

[31] Dutta, J., Fan, Y., Gupta, N., Fan, G., & Gélinas, C. (2006). Current insights into the regulation of programmed cell death by NF-kappaB. *Oncogene*, 25(21), 6800–6816. https://doi.org/10.1038/sj.onc.1209938

[32] Gupta, A. K., McKenna, W. G., Weber, C. N., Feldman, M. D., Goldsmith, J. D., Mick, R., Machtay, M., Rosenthal, D. I., Bakanauskas, V. J., Cerniglia, G. J., Bernhard, E. J., Weber, R. S., & Muschel, R. J. (2002). Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. *Clinical
cancer research: an official journal of the American Association for Cancer Research, 8(3), 885–892.
[33] Li, Q., & Verma, I. M. (2002). NF-kappaB regulation in the immune system. Nature reviews. Immunology, 2(10), 725–734. https://doi.org/10.1038/nn910
[34] Ozes, O. N., Mayo, L. D., Gustin, J. A., Pfeffer, S. R., Pfeffer, L. M., & Donner, D. B. (1999). NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature, 401(6748), 82–85. https://doi.org/10.1038/43466
[35] Downward J. (2004). PI 3-kinase, Akt and cell survival. Seminars in cell & developmental biology, 15(2), 177–182. https://doi.org/10.1016/j.semcdb.2004.01.002
[36] Yarden, Y., & Sliwkowski, M. X. (2001). Untangling the ErbB signalling network. Nature reviews. Molecular cell biology, 2(2), 127–137. https://doi.org/10.1038/35052073
[37] Normanno, N., De Luca, A., Bianco, C., Strizzi, L., Mancino, M., Maiello, M. R., Carotenuto, A., De Feo, G., Caponigro, F., & Salomon, D. S. (2006). Epidermal growth factor receptor (EGFR) signaling in cancer. Gene, 366(1), 2–16. https://doi.org/10.1016/j.gene.2005.10.018
[38] Rabinowits, G., & Haddad, R. I. (2012). Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature. Oral oncology, 48(11), 1085–1089. https://doi.org/10.1016/j.oraloncology.2012.06.016
[39] Fung, C., & Grandis, J. R. (2010). Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert opinion on emerging drugs, 15(3), 355–373. https://doi.org/10.1517/147282214.2010.497754
[40] Grandis, J. R., & Sok, J. C. (2004). Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacology & therapeutics, 102(1), 37–46. https://doi.org/10.1016/j.pharmthera.2004.01.002
[41] Soh, J. W., Lee, E. H., Prywes, R., & Weinstein, I. B. (1999). Novel roles of specific isoforms of protein kinase C in activation of the c-fos serum response element. Molecular and cellular biology, 19(2), 1313–1324. https://doi.org/10.1128/mcb.19.2.1313
[42] Johnson D. E. (2012). Targeting proliferation and survival pathways in head and neck cancer for therapeutic benefit. Chinese journal of cancer, 31(7), 319–326. https://doi.org/10.5732/cjc.011.10404
[43] Laimer, K., Spizzo, G., Gastl, G., Obrist, P., Brunhuber, T., Fong, D., Barbieri, V., Jank, S., Doppler, W., Rasse, M., & Norer, B. (2007). High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: A TMA-based immunohistochemical analysis. Oral Oncology, 43(2), 193–198. https://doi.org/10.1016/j.oraloncology.2006.02.009
[44] Modjtahedi, H., & Essapen, S. (2009). Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anti-cancer drugs, 20(10), 851–855. https://doi.org/10.1097/CAD.0b013e3283330590
[45] Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer, 136(5), E359–E386. https://doi.org/10.1002/ijc.29210

This work is licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.